trametinib

2 · 20 / page

Ask MedXY AI

Latest news

Tag

newsovarian cancertrametinib

Biomarker-Driven Precision in Low-Grade Serous Ovarian Cancer: pERK and MAPK Mutations as Predictors of Trametinib Efficacy

By MedXY|Jan 12, 2026

Highlights Background: The Unique Challenge of Low-Grade Serous Ovarian Cancer Low-grade serous ovarian carcinoma (LGSOC)…

Clinical UpdatesanlotinibKRAS mutation

Targeting the MEK/RTK Axis: A Promising Combination Therapy for KRAS-Mutant Non-Small Cell Lung Cancer

By MedXY|Oct 8, 2025

Combining MEK inhibitor trametinib with pan-RTK inhibitor anlotinib shows high efficacy and manageable toxicity in treating advanced non-G12C KRAS-mutant NSCLC, overcoming adaptive resistance and offering improved clinical outcomes.